Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer~  * Stage IV disease~* At least 1 measurable CNS lesion ≥ 10 mm on T1-weighted gadolinium-enhanced MRI~  * No single brain metastasis that could be treated by surgery~* HER-2 positive primary tumor as defined as IHC3+ or IHC2+ and FISH-positive~* Hormone receptor status: not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Life expectancy ≥ 3 months~* Absolute Neutrophil Count (ANC) ≥ 1,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10g/dL~* Creatinine ≥ 1.5 times upper limit of normal (ULN)~* Albumin ≥ 2.5 g/dL~* Serum bilirubin ≤ 1.5 times ULN (unless due to Gilbert's syndrome)~* ASAT and ALAT ≤ 3 times ULN (≤ 5 times ULN with documented liver metastasis)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception 2 weeks before, during, and for 28 days after completion of study treatment (female) or for 1 week after completion of treatment (male)~* Able to swallow and retain oral medication~* Affiliated to a Social Security System~* No known contraindication to MRI~* No prior or active malignancy, unless disease free for ≥ 10 years~* No other concurrent severe and/or uncontrolled medical disease which could compromise study participation, including any of the following:~  * Infection~ * Cardiac disease (e.g., uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past year, Left Ventricular EJection Fraction (LVEF) \> grade 2)~ * Current active hepatic or biliary disease (except for Gilbert syndrome, asymptomatic gallstones, liver metastasis or stable chronic liver disease per investigator assessment)~ * Renal disease~ * Active gastrointestinal (GI) tract ulceration, malabsorption syndrome, active uncontrolled ulcerative colitis, or disease significantly affecting GI function~ * Severely impaired lung function (e.g., spirometry and diffusion capacity of lung for carbon monoxide (DLCO) ≤ 50% of normal, and O_2 saturation ≤ 88% at rest on room air)~* No known dihydropyrimidine dehydrogenase deficiency~* No significantly altered mental status prohibiting the understanding of the study, or with psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Not deprived of liberty or placed under the authority of a tutor~PRIOR CONCURRENT THERAPY:~* At least 2 weeks since prior breast cancer treatment (e.g., trastuzumab, chemotherapy, immunotherapy or biological response modifiers, endocrine therapy, or radiotherapy)~* More than 30 days since prior investigational drugs~* More than 14 days since prior and no concurrent strong inhibitors or inducers of the cytochrome P450 isoenzyme 3A4 (CYP3A4) (i.e., clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir)~* No prior whole brain radiotherapy (WBRT) or brain stereotactic radiotherapy~* No prior treatment with capecitabine and/or lapatinib ditosylate~* No prior resection of the stomach or small bowel~* No concurrent systemic treatment or radiation therapy for breast cancer (except corticosteroid, bisphosphonates, or mannitol)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib + capecitabine (Type: EXPERIMENTAL): lapatinib 1250mg/day + capecitabine 2000mg/m2/day

Based on this trial design, predict the completion outcome and termination type (if applicable).